FDA Continues to Make Rare Diseases a Priority with Speedy Therapeutic Development

News
Article

FDA’s CDER continues to make rare diseases a priority with drug approvals and programming to speed therapeutic development.

FDA’s Center for Drug Evaluation and Research (CDER) continues to make rare diseases a priority with teams and programs dedicated to speeding up therapeutic development. Both government incentives and scientific advancements have allowed for drug development for rare diseases.

According to CDER Director, Patrizia Cavazzoni, M.D., “A rare disease is any disease that affects less than 200,000 people in the United States. Drug development for the approximately 7000 rare diseases can be complex for many reasons.” There are approximately 30 million people living in the US who have a rare disease. Many of these diseases have little to no available treatments, because of a lack of participants in rare disease clinical trials and limited understanding of the diseases.

The percentage of drugs approved to treat rare or orphan diseases have increased during the past decade. More than half of CDER’s novel drug approvals in 2021 were for orphan diseases.

CDER is continuing to advance drug development for rare diseases by sharing data with the Critical Path Institute and developing the Rare Disease Cures Accelerator-Data and Analytics Platform. The platform provides a database of information on rare diseases, which can aid in standardization and further understanding. CDER is also working to develop publicly available sets of clinical outcome assessments as part of the Standard Core Clinical Outcome Assessment Grant Program. These steps will aid in trial design, endpoint selections, and other important considerations for drug development.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes